BRAF V600E-Positive Multisite Langerhans Cell Histiocytosis in a Preterm Neonate

Abstract

Hemorrhagic pustules with a “blueberry muffin” appearance accompanied by respiratory failure in a neonate present a challenging differential diagnosis that includes infections and neoplasms. We present a case of multiorgan, multisite Langerhans cell histiocytosis (LCH), positive for the oncogenic BRAF V600E mutation, in a preterm neonate. Infants with LCH pose a diagnostic challenge due to their heterogeneous presentations. This case is unusual in that the newborn presented with severe multiorgan involvement. Due to the rare incidence, wide spectrum of clinical manifestations, and high mortality rate, clinicians must maintain a high index of suspicion for LCH.

Keywords

Langerhans cell histiocytosis - BRAF V600E - preterm neonate - multiorgan - multisite - hemorrhagic pustules

• References

• 1 Syridou G, Spanakis N, Konstantinidou A , et al. Detection of cytomegalovirus, parvovirus B19 and herpes simplex viruses in cases of intrauterine fetal death: association with pathological findings. J Med Virol 2008; 80: 1776-1782
• 2 Abdalla KF, el Fakahany AF, Arafa MA, Salama MM, Morsy TA. Congenital toxoplasmosis among premature infants with different clinical pictures in Saudi Arabia. J Egypt Soc Parasitol 1994; 24: 643-648
• 3 Isaacs Jr H. Cutaneous metastases in neonates: a review. Pediatr Dermatol 2011; 28: 85-93
• 4 Bechan GI, Egeler RM, Arceci RJ. Biology of Langerhans cells and Langerhans cell histiocytosis. Int Rev Cytol 2006; 254: 1-43
• 5 Nezelof C, Basset F, Rousseau MF. Histiocytosis X histogenetic arguments for a Langerhans cell origin. Biomedicine 1973; 18: 365-371
• 6 Basset F, Turiaf MJ. [Identification by electron microscope of particles of probable viral nature in the granulomatous connections of a pulmonary histiocytosis “X”]. C R Acad Sci Hebd Seances Acad Sci D 1965; 261: 3701-3
• 7 Cancilla PA, Lahey ME, Carnes WH. Cutaneous lesions of Letterer-Siwe disease. Electron microscopic study. Cancer 1967; 20: 1986-91
• 8 Rousseau-Merck MF, Barbey S, Jaubert F, Bach MA, Chatenoud L, Nezelof C. Reactivity of histiocytosis X cells with monoclonal antibodies. Pathol Res Pract 1983; 177: 8-12
• 9 Geissmann F, Lepelletier Y, Fraitag S , et al. Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood 2001; 97: 1241-1248
• 10 Nezelof C, Frileux-Herbet F, Cronier-Sachot J. Disseminated histiocytosis X: analysis of prognostic factors based on a retrospective study of 50 cases. Cancer 1979; 44: 1824-1838
• 11 Guyot-Goubin A, Donadieu J, Barkaoui M, Bellec S, Thomas C, Clavel J. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000–2004. Pediatr Blood Cancer 2008; 51: 71-75
• 12 Stein SL, Paller AS, Haut PR, Mancini AJ. Langerhans cell histiocytosis presenting in the neonatal period: a retrospective case series. Arch Pediatr Adolesc Med 2001; 155: 778-783
• 13 Newman B, Hu W, Nigro K, Gilliam AC. Aggressive histiocytic disorders that can involve the skin. J Am Acad Dermatol 2007; 56: 302-316
• 14 Minkov M, Prosch H, Steiner M , et al. Langerhans cell histiocytosis in neonates. Pediatr Blood Cancer 2005; 45: 802-807
• 15 Allen CE, Li L, Peters TL , et al. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol 2010; 184: 4557-4567
• 16 Degar BA, Rollins BJ. Langerhans cell histiocytosis: malignancy or inflammatory disorder doing a great job of imitating one?. Dis Model Mech 2009; 2: 436-439
• 17 Querings K, Starz H, Balda BR. Clinical spectrum of cutaneous Langerhans' cell histiocytosis mimicking various diseases. Acta Derm Venereol 2006; 86: 39-43
• 18 Badalian-Very G, Vergilio JA, Degar BA , et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010; 116: 1919-1923
• 19 Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS. BRAF(E600) in benign and malignant human tumours. Oncogene 2008; 27: 877-895
• 20 Gadner H, Grois N, Pötschger U , et al; Histiocyte Society. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 2008; 111: 2556-2562
• 21 Chapman PB, Hauschild A, Robert C , et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516
• 22 Hauschild A, Grob JJ, Demidov LV , et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365
• 23 Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, Cluzel P, Drier A, Hervier B, Benameur N, Besnard S, Donadieu J, Amoura Z. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood , February 28, 2013; 121 (9); 1495-500